Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BW-02
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $4,165.0 million
Deal Type : Licensing Agreement
Shanghai Argo Announces RNAi Licenses and Collaborations with Novartis
Details : Argo has granted Novartis global licenses to develop and commercialize a Phase 1 program, allowing Novartis to select targets and drive discovery and optimization of lead candidates.
Brand Name : BW-02
Molecule Type : Large molecule
Upfront Cash : $185.0 million
January 07, 2024
Lead Product(s) : BW-02
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : $4,165.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
